Laboratory-Treated T Cells in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Recurrent or Refractory B-Cell Lymphoma or Multiple Myeloma

Inclusion Criteria

• INCLUSION CRITERIA FOR BLOOD PROCUREMENT:
• B-CLL or recurrent or refractory B-cell lymphoma (or other B-cell neoplasm) or multiple myeloma monoclonal for Kappa-light chain
• Life expectancy of at least 12 weeks or greater
• No history of other cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer) unless the tumor was successfully treated with curative intent at least 2 years before trial entry
• If requires pheresis to collect blood, creatinine (Cre) < 1.5 upper limit of normal
• If requires pheresis to collect blood, aspartate aminotransferase (AST) < 1.5 upper limit of normal
• If requires pheresis to collect blood, prothrombin time (PT) < 1.5 upper limit normal
• If requires pheresis to collect blood, partial thromboplastin time (kaolin) (PTTK) < 1.5 upper limit normal
• INCLUSION CRITERIA FOR T CELL TREATMENT:
• Diagnosis of: * B-CLL monoclonal for Kappa light chain with one or more of the following criteria: ** Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia ** Massive (i.e., at least 6 cm below the left costal margin) or progressive or symptomatic splenomegaly ** Massive nodes (i.e., at least 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy ** Progressive lymphocytosis with an increase of more than 50% over a 2-month period or lymphocyte doubling time (LDT) of less than 6 months ** Constitutional symptoms, defined as any one or more of the following disease-related symptoms or signs: *** Unintentional weight loss of 10% or more within the previous 6 months; *** Significant fatigue (i.e., Eastern Cooperative Oncology Criteria [ECOG] performance status [PS] 2 or worse; inability to work or perform usual activities); *** Fevers higher than 100.5°F or 38.0°C for 2 or more weeks without other evidence of infection; or *** Night sweats for more than 1 month without evidence of infection *** Patients who have resistant disease after primary treatment *** Patients who have a short time to progression after the first treatment (< 2 years) OR * Indolent or aggressive B-cell lymphoma (or other B-cell neoplasm) monoclonal for Kappa-light chain with measurable disease after receiving at least one chemotherapy regimen that includes rituximab or an equivalent monoclonal antibody OR * Multiple myeloma monoclonal for Kappa-light chain with measurable disease after receiving at least one chemotherapy regimen
• Life expectancy of at least 12 weeks or greater
• Recovered from the toxic effects of all prior chemotherapy before entering this study
• Absolute neutrophil count (ANC) > 500
• Hemoglobin (HgB) > 8.0
• Bilirubin less than 3 times the upper limit of normal
• AST less than 5 times the upper limit of normal
• Serum creatinine less than 3 times upper limit of normal
• Pulse oximetry of > 90% on room air
• Karnofsky score of > 60%
• Negative serology for human immunodeficiency virus (HIV)
• Available autologous transduced peripheral blood T-cells with >= 15% expression of CAR-Kappa determined by flow-cytometry
• Patients must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects; patients will be given a copy of the consent form
• Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 3 months after the study is concluded; the male partner should use a condom
• If patient has CLL must have a negative Coombs test

Exclusion Criteria

• EXCLUSION CRITERIA FOR BLOOD PROCUREMENT:
• Active infection requiring antibiotics
• Active autoimmune disease
• EXCLUSION CRITERIA FOR T CELL TREATMENT:
• Symptomatic cardiac disease
• History of hypersensitivity reactions to murine protein-containing products
• Currently receiving any investigational agents within the previous six weeks or received any tumor vaccines within the previous 6 weeks
• Tumor in a location where enlargement could cause airway obstruction
• Pregnant or lactating